Search Results

You are looking at 81 - 90 of 569 items for :

  • Refine by Access: All x
Clear All
Full access

CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

Yazan Madanat, Michael R. Savona, Mikkael A. Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Fei Huang, Shyamala Navada, Rami S. Komrokji, and Amer M. Zeidan

secondary endpoints included 8- and 24-wk TI, hematologic improvement-erythroid (HI-E), duration of TI, and safety. Cytogenetic response (IWG 2006), VAF changes, and patient-reported fatigue were exploratory endpoints. Results: At baseline, median age was

Full access

Letter to the Editor: Chicken Noodle Soup (Capsule) for the Soul?

Lindsey A. Kluck and Ronald S. Go

Re: Sriram Yennurajalingam, Nizar M. Tannir, Janet L. Williams, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients with Advanced Cancer. J Natl Compr Canc Netw 2017

Full access

Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg

. Factors influencing quality of life in cancer patents: anemia and fatigue . Semin Oncol 1998 ; 25 : 43 – 46 . 4 Curt GA . Impact of fatigue on quality of life in oncology patients . Semin Hematol 2000 ; 37 : 14 – 17 . 5 Sobrero

Full access

Erratum

;21[5]: 473–479.e4 ; doi: 10.6004/jnccn.2022.7101 ), Figure 1 was printed incorrectly. The starting points of the lines for G3 fatigue; G2 nausea; and G1 anemia should have been positioned farther to the right. The figure is printed correctly below

Full access

CLO20-061: A Meta-Analysis on the Safety of Panobinostat Compared to Eltozumab and Ixazomib for the Treatment of Multiple Myeloma

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat, and Qian Zhang

.11) Figure 1 . Paobinostat had a significantly lower risk of lymphopenia (OR 0.25 95% CI 0.15-0.42, p=<0.0001) Panobinostat was however, associated with two times more risk of anemia (OR 2.82 95% CI 1.82-4.38, p=<0.0001), fatigue (OR 2.36 95% CI 1.64-3.38, p

Full access

NCCN News

needs and priorities. November marked the publication of a new NCCN Guidelines for Patients: Palliative Care , part of an ongoing expansion of supportive care resources. The new NCCN Guidelines for Patients: Fatigue and Cancer has also been published

Full access

Relationship Between Hemoglobin Levels and Quality of Life During Radiation Therapy Plus Concomitant or Sequential Chemotherapy in Patients With Cancer and Anemia Treated With Epoetin Alfa

Daniel Shasha, Pierre Cremieux, and Louis Harrison

patients undergoing radiation therapy . Semin Oncol 2001 ; 28 ( suppl 8 ): 54 – 59 . 4 Irvine D Vincent L Graydon JE . The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy: A comparison

Full access

CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation

Mustafa Özgüroğlu, Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Xuanyao He, Jennifer McGinniss, Giuseppe Gullo, Petra Rietschel, and Ruben GW Quek

statistically significant favorable difference in overall change from baseline in role functioning (8.59; 95% CI, 0.16, 17.01; p=0.0459), emotional functioning (7.27; 95% CI, 1.86, 12.69; p=0.0095), and symptoms of fatigue (-8.19; 95% CI, -15.40, -0.98; p=0

Full access

HSR20-087: Prevalence and Correlates of Psychological Distress in Patients Enrolling on Phase I Clinical Trials Using the NCCN Distress Thermometer and Problem List

Alexandra Hunt, Elizabeth Handorf, Vipin Khare, Matthew Blau, Yana Chertock, Carolyn Fang, Michael J. Hall, and Rishi Jain

evaluate the frequency of specific stressors including: practical (e.g. insurance/financial), family (e.g. family health issues), emotional (e.g. nervousness), or physical (e.g. fatigue). Adverse events on trial including hospitalizations, toxicities, or

Full access

QIM24-186: Surviving and Thriving After Lung Cancer: A Pilot Project to Understand Physician Perspectives on the Approach to Lung Cancer Survivorship Care at Weill Cornell Medicine Medical Oncology

Abha Kulkarni and Christine Garcia

), smoking cessation (12), and fatigue (11). The concerns that most respondents felt comfortable addressing were breathing difficulties (% comfortable=100), cough (92), pain (92), smoking cessation (92), fatigue (83), mobility and exercise (67), and emotional